After a year of planning and just after Labor Day, we headed back “home” to visit our native state, re-connect with friends ...

Editor in chief Nancy Shute discusses efforts of Indigenous people in British Columbia to preserve ancient trails.

Federal Conservative Leader Pierre Poilievre is riding a wave of popularity in most parts of Canada these days, but you wouldn't know it if you asked the leader of Nova Scotia's incumbent Progressive ...

ACADIA Pharmaceuticals Inc. ( (ACAD) ) has released its Q3 earnings. Here is a breakdown of the information ACADIA Pharmaceuticals Inc.

Friends of Acadia’s 2024 Take Pride in Acadia Day brought out enthusiastic volunteers of all ages to rake leaves and clear ...

NUPLAZID net product sales guidance is narrowed to the high end of the prior range and is now expected to be $600 to $610 million. DAYBUE net ...

SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced today that Health Canada has approved DAYBUE™ (trofinetide) for treating Rett syndrome in adults and children aged two and older.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett ...

Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome in adult and paediatric patients aged two years and above.

DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder SAN DIEGO, October 16, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals ...

Acadia Healthcare (NASDAQ:ACHC) Company, Inc. (NASDAQ:ACHC), a leading provider of behavioral healthcare services in the United States, finds itself at a critical juncture as it navigates a ...